

Curriculum vitae
Jenny Bulgarelli

ORCID: 0000-0002-6551-0189, **Research ID:** AAB-6083-2021, **Scopus ID:** 55248386300

Date of birth: 03/01/1986

Nationality: Italian

EDUCATION

02/2024-24/03/2025	Second-level Master's degree in "Immuno-Oncology and Cellular Therapies" from Sapienza University of Rome.
01/2011-04/2014	Ph.D., Molecular and Regenerative Medicine, University of Modena and Reggio Emilia, Italy.
03/2011	Qualification as a Professional Biologist (Licensed as a Biologist from 01/2019) University of Modena and Reggio Emilia, Italy.
11/2008-10/2010	Specialistic's Degree, Medical and pharmaceutical Biotechnology, University of Modena and Reggio Emilia, Italy.
09/2005-10/2008	Bachelor's Degree, Biotechnology, University of Modena and Reggio Emilia, Italy.

CURRENT POSITIONS

11/2014-present	Postdoc Researcher (permanent position from April 2022), as referent person of the Clinical and experimental Immune monitoring platform at Advanced Cell Therapies and Rare Tumours. IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST). Via Piero Maroncelli 40, Meldola (FC) 47014, Italy.
-----------------	---

PAST POSITIONS

11/2015-05/2022	Fixed-term post-doctoral research contract at the IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" S.r.l. in the Immunotherapy, Cell Therapy and Biobank Unit. Field of research: Immunomonitoring and analysis of antigen-specific response in patients treated with dendritic cell vaccines and other immunotherapies. Study of the heterogeneity of melanoma tumour cells in relation to response or resistance to therapy.
11/2014-11/2015	Annual research fellow at the Immunotherapy, Cell Therapy and Biobank Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" S.r.l.
06/2017	Visiting Scientist, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), ILLKIRCH, France.
09/2013-08/2014	Research fellow, Laboratory of hematopoietic stem cells, Centre for Regenerative Medicine "Stefano Ferrari", Department, University of Modena and Reggio Emilia, Italy.
05/2011-04/2013	PhD student with a research fellow, Laboratory of experimental hematology, Department of Medical and Surgical Science, University of Modena and Reggio Emilia, Italy.

AWARDS AND HONORS

10/2022	Winner as CoPI of Bando "Giovani Ricercatori- Ricerca Finalizzata 2021 provided by the Italian Ministry of Health. Project Title: Nanotechnology-based Platforms for the improvEment of therapeutic strateGies in soft tissue sArcoma and melanoma leSiOns (PEGASO)
---------	---

05/2016	14th CIMT Annual Meeting Travel Award winner Poster presentation: "The double face of dendritic cell vaccination in metastatic melanoma: inducing intratumor immune response can switch tumor cells toward dedifferentiated state." <i>Bulgarelli J*, Ancarani V, Pancisi E, Petrini M, Riccobon A, Fiammenghi L, Cassan S, Soldati V, Ridolfi L, De Rosa F, Gentili G, Amadori D, Ridolfi R, Guidoboni M, Granato A.M.</i>
---------	--

SPECIFIC TRAININGS

17/06/2025	"Le nuove Linee Guida di Buona Pratica Clinica GCP E6 (R3): analisi dei cambiamenti qualitativi e dell'impatto nella pratica degli studi clinici". IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori".
15/06/2023	"Good Clinical Practice: dalla teoria alla pratica". IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori".
24/03/2021	"Good Clinical Practice (Investigator Version), version #2.1. Roche/Genentech.
10-11/10/2016	Corso di CTP System "Novità in ambito normative sulle terapie avanzate" e "Analisi del rischio ed applicazioni in ambito GMP". IRCCS Istituto scientifico romagnolo per lo studio e la cura dei tumori, Italy
28/09-02/10/2015	Next generation sequencing (NGS) data analysis. IRCCS Istituto scientifico romagnolo per lo studio e la cura dei tumori, Italy.
23-25/10/2012	"Ion Torrent" instrument use for next-generation sequencing applications. CGR, University of Modena and Reggio Emilia, Italy.
19/10/2012	IFOM-IEO External Seminar "Coupling Cell function to Cell Migration: the example of Dendritic Cells". IFOM-IEO Campus Milano.
18/10/2012	IFOM-IEO External Seminar "Aneuploidy in cellular adaptation, drug resistance and cancer". IFOM-IEO Campus Milano.
09/06/2012	GIC Seminar "La citometria e le sue applicazioni", Brescia.
12-13/09/2011	Bioinformatics Course "EuGESMA Bioinformatics School 2011". CGR, University of Modena and Reggio Emilia, Italy.
22/02/2011	THE NGS DAY 2011 "The first Unimore workshop on next generation sequencing". University of Modena and Reggio Emilia, Italy.

SUPERVISION OF GRADUATE STUDENTS

05-10/2025	Supervision of a student in Biotechnology (Dr. Ludovico Billi Campana), Bachelor's degree, University of Bologna, Italy.
11/2018-02/2020	Supervision of a graduate student in Biology (Dr. Claudia Piccinini), Master Degree, University of Bologna, Italy.
01-09/2013	Supervision of a student in Biotechnology (Dr. Maria Giulia Nozzi), Bachelor's Degree, University of Modena and Reggio Emilia, Italy.

ORGANISATION OF SCIENTIFIC MEETINGS

17-19/09/2025	Faculty member of the congress "V CONVEGNO ITALIANO SULLE TERAPIE AVANZATE E RADIOFARMACI", Centro Congressi SGR, Rimini, Italy.
04-05/05/2023	Faculty member of the congress "GLIOBLASTOMA: NUOVI ORIZZONTI NELL'ERA DELLA TERAPIA PERSONALIZZATA", IRCCS IRST, Meldola, Italy.
13/09/2023	Faculty member of the congress "PERSONALIZED MEDICINE IN LOCALLY ADVANCED RESECTABLE GASTRIC CANCER: WHERE WE ARE, WHERE WE ARE GOING", IRCCS IRST, Meldola, Italy.
28-29/10/2022	Member of the Organizing Committee of the 4th International Translational Courses in Rare Cancers, IRCCS IRST, Meldola, Italy.

17-18/12/2020	Member of the Organizing Committee of the 3rd International Translational Courses in Rare Cancers, IRCCS IRST, Meldola, Italy.
24/05/2019	Member of the Organizing Committee of "Immunologia dei tumori: tutto quello che vorreste sapere ma non hai il coraggio di chiedere", IRCCS IRST, Meldola, Italy.

ORAL PRESENTATIONS

19/09/2025	V CONVEGNO ITALIANO SULLE TERAPIE AVANZATE E RADIOFARMACI. "The Critical Role of Immune Monitoring in Clinical Trials Involving ATMPs". Centro Congressi SGR, Rimini.
04-05/05/2023	Glioblastoma-nuovi orizzonti nell'era della terapia personalizzata. "Monitoraggio della risposta immune in clinica". IRCCS-IRST Meldola.
28-29/10/2022	4th International Translational Course in Rare Cancers (ITCRC). "New technologies to answer open questions: Multi-omics approaches for immune monitoring and tumor microenvironment investigation in solid tumors"
13/09/2022	Discussant at "PERSONALIZED MEDICINE IN LOCALLY ADVANCED RESECTABLE GASTRIC CANCER: WHERE WE ARE, WHERE WE ARE GOING". IRCCS-IRST Meldola.
20-23/10/2013	44° Congresso Nazionale SIE 2013, Verona, Italy. "Endothelin-1/ETA receptor signalling mediates growth and proliferative signals in Chronic Lymphocytic Leukemia cells"

POSTER PRESENTATIONS

20-23/09/2023	7th International Cancer Immunotherapy Conference CICON 2023. "Personalized adjuvant dendritic cells vaccination in Melanoma patients: Insights into immunological landscape". Milan, Italy.
07-09/12/2022	ESMO Immuno-Oncology Annual Meeting 2022, Geneva Switzerland. "Exploiting multi-omic integrated data from DC-vaccinated melanoma patients for the generation of an advanced adoptive T cell therapy"
11-14/12/2019	ESMO Immuno-Oncology Annual Meeting 2019, Geneva Switzerland. "Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with High-Dose Interleukin-2 (HDIL2): final data"
10-12/05/2016	14th CIMT Annual Meeting 2016, Mainz, Germany. "The double face of dendritic cell vaccination in metastatic melanoma: inducing intratumor immune response can switch tumor cells toward dedifferentiated state"
16-19/10/2011	43° Congresso Nazionale SIE 2011, Napoli, Italy. "Altered composition of circulating monocytic population in chronic lymphocytic leukemia B-cells patients"

INSTITUTIONAL RESPONSIBILITIES

2020- present	Referent person of the Clinical and Experimental Immune monitoring platform
2020- present	Consultant for the acquisition of the following laboratory equipment: plate fluorometer (member of the evaluating commission), Protein Simple ELLA System Immunoassay platform (technical specifications writing consultant)

REVIEWING ACTIVITIES

2018- present	Invited reviewer for scientific journals (Cancers, Vaccines, International Journal of Molecular Sciences, Frontiers in Immunology Nature Communications). On-call editor for special issues (Vaccines, Cancers)
---------------	---

MEMBERSHIPS OF SCIENTIFIC SOCIETIES

2022 and 2025	Member of European Society For Medical Oncology ESMO
2023	Member of the Network Italiano per la Bioterapia dei Tumori (NIBIT)
From 2022-present	Member of the Network Officine Terapie Avanzate APS (NOTA)
2020	Member of the Society for Immunotherapy of Cancer (SITC)

MAJOR COLLABORATIONS

- Dept. of Dermatology Amsterdam UMC (Marcella Willemsen, Walbert Bakker and Rosalie Luiten) Melanoma heterogeneity_TRANSCAN-2
- Dept. of Oncology, Oslo University Hospital Radiumhospitalet (Kyte J.A and Sudhir Kumar Chauhan) Melanoma heterogeneity_TRANSCAN-2
- CNRS/INSERM IGBMC, France (Irwin Davidson) Melanoma heterogeneity_TRANSCAN-2
- Medical Genetics Unit, AUSL Romagna, Cesena, Italy (Dott.ssa Laura Renzi)_HLA anatomy project
- Alliance against cancer (ACC) Melanoma working group and Immunotherapy working group

PUBLICATIONS

1. Comparative Analysis of Library Preparation Approaches for FFPE Gene Expression Profiling and Related Recommendations. *Pignatta S, et al. Bulgarelli J (Last)*. Sci Rep 2025 Aug 12;15(1):29592. doi: 10.1038/s41598-025-12992-7.
2. Adjuvant dendritic cell-based immunotherapy in melanoma: insights into immune cell dynamics and clinical evidence from a phase II trial. *Bulgarelli J, et al.* J Transl Med. 2025 Apr 18;23(1):455. doi: 10.1186/s12967-025-06403-8.
3. Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy. *M Willemsen*; J. Bulgarelli*; et al.* (*these authors contributed equally to this work). Immunooncol Technol. 2024 Nov 15;24:101009. doi: 10.1016/j.iotech.2024.101009.
4. First step results from a Phase II Study of a Dendritic cell vaccine in Glioblastoma patients (CombiG-vax). *Ridolfi L, et al.* Front Immunol. 2024 Aug 13;15:1404861. doi: 10.3389/fimmu.2024.1404861.
5. Dendritic cell vaccines as cancer treatment: focus on 13 years of manufacturing and quality control experience in advanced therapy medicinal products. *Granato AM, et al. Bulgarelli J corresponding author*. Cytotherapy. 2024 Dec;26(12):1547-1555. doi: 10.1016/j.jcyt.2024.07.005.
6. Sequencing of checkpoint or BRAF/MEK inhibitors on brain metastases in melanoma. *Ascierto P, et al.* NEJM Evid. 2024 Oct;3(10):EVIDoa2400087. doi: 10.1056/EVIDoa2400087.
7. Comprehensive Genomic Profiling on Metastatic Melanoma: results from a network screening from 6 Italian Cancer Centres. *Matteo Pallocca, et al.* J Transl Med. 2024 Jan 6;22(1):29. doi: 10.1186/s12967-023-04776-2.
8. 4-year survival and biomarkers evaluation from a phase II study of sequential immunotherapy and targeted therapy for metastatic BRAF V600-mutated melanoma (SECOMBIT). *Milena Casula, Jenny Bulgarelli, Marina Pisano, Claudia Piccinini, Luisa Piccin, Antonio Cossu, Mario Mandala, Dr Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Fierro, Celeste Lebbé, Hildur Helgadóttir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzalez-Cao, Alessandro Minisini, Sabino De Placido, Miguel Sanmamed, Domenico Mallardo, Miriam Paone, Maria Vitale, Ignacio Melero, Antonio Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion-Sileni, Giuseppe Palmieri*. Under revision in Nature Communications.
9. Immuno Markers in Newly Diagnosed Glioblastoma Patients Underwent Stupp Protocol after Neurosurgery: A Retrospective Series. *Gurrieri L, Mercatali L, Ibrahim T, Fausti V, Dall'Agata M, Riva N, Ranallo N, Pasini G, Cocchi C, Tazzari M, Foca F, Bartolini D, Riccioni L, Cavatorta C, Morigi FP, Bulgarelli J, Ghini V, Tosatto L, Pession A, Ridolfi L.* J Neurooncol. 2023 Aug 16. doi: 10.1007/s11060-023-04357-9.

10. The Renewal of Cancer Immunotherapy. **Jenny Bulgarelli**, Sara Pignatta *, Massimiliano Petrini and Laura Ridolfi. *Editorial in Vaccines* (Basel). 2023 Mar 4;11(3):592. DOI: 10.3390/vaccines11030592
11. Stability Program in Dendritic Cell Vaccines: A "Real-World" Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center. Elena Pancisi, Anna Maria Granato, Emanuela Scarpi, Laura Ridolfi, Silvia Carloni, Cinzia Moretti, Massimo Guidoboni, Francesco De Rosa, Sara Pignatta, Claudia Piccinini, Valentina Soldati, Luana Calabrò, Massimo Framarini, Monica Stefanelli, **Jenny Bulgarelli**, Marcella Tazzari, Francesca Fanini, Massimiliano Petrini. *Vaccines* (Basel) 2022 Jun 23;10(7):999. doi: 10.3390/vaccines10070999.
12. Radiotherapy and high-dose interleukin-2: clinical and immunological results of a proof of principle study in metastatic melanoma and renal cell carcinoma. **Bulgarelli J**, Piccinini C, Petracci E, Pancisi E, Granato AM, De Rosa F, Guidoboni M, Petrini M, Ancarani V, Foschi G, Romeo A, Tontini L, De Giorgi U, Lolli C, Gentili G, Valmorri L, Rossi A, Ferroni F, Casadei C, Cortesi P, Crudi L, Ridolfi L. *Front Immunol*. 2021 Oct 27;12:778459. doi: 10.3389/fimmu.2021.778459.
13. Effects of a Diet Based on Foods from Symbiotic Agriculture on the Gut Microbiota of Subjects at Risk for Metabolic Syndrome. Turroni S, Petracci E, Edefonti V, Giudetti AM, D'Amico F, Paganelli L, Giovannetti G, Del Coco L, Fanizzi FP, Rampelli S, Guerra D, Rengucci C, **Bulgarelli J**, Tazzari M, Pellegrini N, Ferraroni M, Nanni O, Serra P. *Nutrients*. 2021 Jun 17;13(6):2081. doi: 10.3390/nu13062081.
14. Dendritic cell vaccination in metastatic melanoma turns "non-T cell inflamed" into "T-cell inflamed" tumors. **Bulgarelli J**, Tazzari M, Granato AM, Ridolfi L, Maiocchi S, de Rosa F, Petrini M, Pancisi E, Gentili G, Vergani B, Piccinini F, Carbonaro A, Leone BE, Foschi G, Ancarani V, Framarini M, Guidoboni M. *Front Immunol*. 2019 Oct 9;10:2353. doi: 10.3389/fimmu.2019.02353.
15. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial). Ridolfi L, de Rosa F, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, **Bulgarelli J**, Riccobon A, Gentili G, Nanni O, Framarini M, Tauceri F, Guidoboni M. *BMJ Open*. 2018 Aug 5;8(8):e021701.
16. Skewing effect of sulprostone on dendritic cell maturation compared with dinoprostone. **Bulgarelli J**, Fiammenghi L, Cassan S, Granato AM, Petrini M, Pancisi E, Soldati V, De Rosa F, Ridolfi L, Riccobon A, Guidoboni M. *Cytotherapy*. 2018 Jun 10. pii: S1465-3249(18)30485-7.
17. Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience. De Rosa F, Ridolfi L, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, **Bulgarelli J**, Framarini M, Tauceri F, Migliori G, Brolli C, Gentili G, Petracci E, Nanni O, Riccobon A, Ridolfi R, Guidoboni M. *Melanoma Res*. 2017 Aug;27(4):351-357.
18. Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. Maffei R, Fiorcari S, Martinelli S, Benatti S, **Bulgarelli J**, Rizzotto L, Debbia G, Santachiara R, Rigolin GM, Forconi F, Rossi D, Laurenti L, Palumbo G, Vallisa D, Cuneo A, Gaidano G, Luppi M, Marasca R. *Leuk Lymphoma*. 2018 Feb 22:1-11.
19. c-myc controls erythroid versus megakaryocyte lineage fate decision through the miR-486-3p-mediated down-regulation of c-maf. Bianchi E, **Bulgarelli J**, Sacchi G, Ruberti S, Norfo I, Rontauturoli S, Pennucci V, Zini R, Salati S, Prudente Z, Ferrari S, and Manfredini R. *Cell Death & Differentiation* 2015 Dec;22(12):1906-21.
20. Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. Fiorcari S, Martinelli S, **Bulgarelli J**, Audrito V, Zucchini P, Colaci E, Potenza L, Narni F, Luppi M, Deaglio S, Marasca R, and Maffei R. *Haematologica*. 2014 Nov 14. pii: haematol.2014.113217.
21. Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptor. Maffei R, * **Bulgarelli J**, * Fiorcari S, * Martinelli S, Castelli I, Valenti V, Rossi D, Bonacorsi G, Zucchini P, Potenza L, Vallisa D, Gattei V, Del Poeta G, Forconi F, Gaidano G, Narni F, Luppi M, Marasca R. *PlosOne*. 2014 Jun 5;9(6):e98818. (* these authors contributed equally to this work)
22. Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. Maffei R, Fiorcari S, **Bulgarelli J**, Rizzotto L,

- Martinelli S, Rigolin GM, Debbia G, Castelli I, Bonacorsi G, Santachiara R, Forconi F, Rossi D, Laurenti L, Palumbo GA, Vallisa D, Cuneo A, Gaidano G, Luppi M, Marasca R. Experimental Hematology Journal. 2014 Feb;42(2):126-36.*
23. ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia. *Martinelli S, Kanduri M, Maffei R, Fiorcari S, **Bulgarelli J**, Marasca R and Rosenquist R. Epigenetics. 2013 Jul 1;8(7):720-9.*
 24. Monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. *Maffei R, **Bulgarelli J**, Fiorcari S, Bertoncelli L, Martinelli S, Guarnotta C, Castelli I, Deaglio S, Debbia G, De Biasi S, Bonacorsi G, Zucchini P, Narni F, Tripodo C, Luppi M, Cossarizza A, Marasca R. Haematologica. 2013 Jan 24.*
 25. Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. *Marasca R, Maffei R, Martinelli S, Fiorcari S, **Bulgarelli J**, Debbia G, Rossi D, Rossi FM, Rigolin GM, Martinelli S, Gattei V, Del Poeta G, Laurenti L, Forconi F, Montillo M, Gaidano G, Luppi M. Hematol Oncol. 2012 Oct 2.*
 26. Physical contact with endothelial cells through β 1- and β 2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells. *Maffei R, Fiorcari S, **Bulgarelli J**, Martinelli S, Castelli I, Deaglio S, Debbia G, Fontana M, Coluccio V, Bonacorsi G, Zucchini P, Narni F, Torelli G, Luppi M, Marasca R. Haematologica. 2012 Jun; 97(6):952-60. Epub 2011 Dec 29.*

H-index: 12; excluding self citations: 11 (Scopus)

"La sottoscritta in merito al trattamento dei dati personali esprime il proprio consenso al trattamento degli stessi nel rispetto delle finalità e modalità di cui al d.lgs. n. 196/2003."

"La sottoscritta, consapevole che – ai sensi dell'art. 76 del D.P.R. 445/2000 – le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali, dichiara che le informazioni rispondono a verità."

Meldola, 18/09/2025

Dr. Jenny Bulgarelli, PhD